Formycon Plans Ranibizumab Filings With Ustekinumab And Aflibercept In The Wings
Formycon will follow a US filing for ranibizumab before the end of this year with a European submission early in 2020 as it continues work on biosimilar ustekinumab and aflibercept.
You may also be interested in...
Formycon Delay Pushes Back Coherus’ Ranibizumab
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
Formycon Begins Biosimilar Ustekinumab Trial
Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.
Sandoz Reveals Biosimilar Denosumab Program
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.